OSR Holdings, Inc. and OSR Holdings Co., Ltd. Announce Completion of Business Combination
OSR Holdings, Inc. (formerly Bellevue Life Sciences Acquisition Corp.) and OSR Holdings Co., have successfully completed their business combination. Following this merger, the company will operate under the name OSR Holdings, Inc. Starting Tuesday, February 18, 2025, the company's common stock and warrants will begin trading on the Nasdaq Stock Market under the new ticker symbols 'OSRH' and 'OSRHW' respectively.
OSR Holdings, Inc. (precedentemente Bellevue Life Sciences Acquisition Corp.) e OSR Holdings Co. hanno completato con successo la loro fusione aziendale. A seguito di questa fusione, l'azienda opererà con il nome OSR Holdings, Inc. A partire da martedì 18 febbraio 2025, le azioni ordinarie e i warrant della società inizieranno a essere scambiati sul Nasdaq Stock Market con i nuovi simboli ticker 'OSRH' e 'OSRHW' rispettivamente.
OSR Holdings, Inc. (anteriormente Bellevue Life Sciences Acquisition Corp.) y OSR Holdings Co. han completado con éxito su combinación empresarial. Tras esta fusión, la empresa operará bajo el nombre de OSR Holdings, Inc. A partir del martes 18 de febrero de 2025, las acciones ordinarias y los warrants de la empresa comenzarán a cotizar en el Nasdaq Stock Market bajo los nuevos símbolos de ticker 'OSRH' y 'OSRHW' respectivamente.
OSR Holdings, Inc. (이전 Bellevue Life Sciences Acquisition Corp.)와 OSR Holdings Co.가 성공적으로 사업 결합을 완료했습니다. 이번 합병 후, 회사는 OSR Holdings, Inc.라는 이름으로 운영됩니다. 2025년 2월 18일 화요일부터 회사의 보통주와 워런트는 Nasdaq Stock Market에서 새로운 티커 기호 'OSRH'와 'OSRHW'로 거래를 시작합니다.
OSR Holdings, Inc. (anciennement Bellevue Life Sciences Acquisition Corp.) et OSR Holdings Co. ont réussi à finaliser leur combinaison d'affaires. Suite à cette fusion, l'entreprise fonctionnera sous le nom de OSR Holdings, Inc. À partir du mardi 18 février 2025, les actions ordinaires et les warrants de l'entreprise commenceront à être négociés sur le Nasdaq Stock Market sous les nouveaux symboles boursiers 'OSRH' et 'OSRHW' respectivement.
OSR Holdings, Inc. (früher Bellevue Life Sciences Acquisition Corp.) und OSR Holdings Co. haben erfolgreich ihre Unternehmenszusammenlegung abgeschlossen. Nach dieser Fusion wird das Unternehmen unter dem Namen OSR Holdings, Inc. tätig sein. Ab dem Dienstag, den 18. Februar 2025 werden die Stammaktien und Warrants des Unternehmens an der Nasdaq Stock Market unter den neuen Tickersymbolen 'OSRH' und 'OSRHW' gehandelt.
- Successful completion of business combination
- Uplisting to Nasdaq Stock Market
- New trading symbols established for both common stock and warrants
- None.
Insights
The successful completion of the business combination between Bellevue Life Sciences Acquisition Corp. (BLAC) and OSR Holdings represents a pivotal transaction in the SPAC landscape. This merger marks the culmination of BLAC's mission as a Special Purpose Acquisition Company, effectively transforming it from a blank check company into an operating business through the combination with OSR Holdings.
For current BLAC shareholders, this completion triggers several important mechanisms: their shares will automatically convert to the new entity's common stock, trading under the ticker symbol OSRH. Similarly, existing warrants will transition to trade under OSRHW. The trading initiation on February 18 under the new symbols represents the final step in the de-SPAC process.
The successful completion indicates that all necessary shareholder approvals, regulatory requirements, and closing conditions have been met. This transition from BLAC to OSRH signifies the merger's effectiveness and the beginning of the combined company's journey as a publicly traded entity. The seamless execution of this business combination, particularly in the current market environment where many SPAC deals face challenges, suggests strong institutional support and investor confidence in the merger's strategic rationale.
OSR Holdings, Inc. to Begin Trading on the Nasdaq Stock Market LLC on Tuesday, February 18, 2025
Under the symbol "OSRH"
The Company now operates as "OSR Holdings, Inc." following the successful completion of the Business Combination. Beginning on Tuesday, February 18, 2025, the common stock and warrants of the Company are expected to begin trading on the Nasdaq Stock Market LLC under the ticker symbols "OSRH" and "OSRHW," respectively.
About OSR Holdings, Inc.
OSR Holdings, Inc. was a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Following the successful completion of the Business Combination, the Company now owns approximately
About OSR Holdings Co., Ltd.
OSR is a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families. OSR aims to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. Its current operating businesses (through three wholly-owned subsidiaries) include (i) developing oral immunotherapies for the treatment of cancer, (ii) developing design-augmented biologics for age-related and other degenerative diseases and (iii) neurovascular intervention medical device and systems distribution in
Forward Looking Statements
This communication includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "goal," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target," "continue," "could," "may," "might," "possible," "potential," "predict" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding expectations and timing related to the execution of OSR's mission to build and develop a robust portfolio of innovative and potentially transformative therapies and healthcare solutions. These forward-looking statements are based on information available to us as of the date of this communication and represent management's current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve known and unknown risks, uncertainties and other factors, which may be beyond our control.
These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of the Company and OSR's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of the Company and OSR. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about the Company and OSR that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include risks related to OSR's ability to execute on its strategy; regulatory uncertainties; the potential need for financing to sustain the Company; market, financial, political and legal conditions; the effects of competition; changes in applicable laws or regulations; and the outcome of any government and regulatory proceedings, investigations and inquiries. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by the forward-looking statements. There may be additional risks that we do not presently know or that we currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect our expectations, plans or forecasts of future events and views as of the date of this communication. We anticipate that subsequent events and developments will cause our assessments to change. However, while we may elect to update these forward-looking statements at some point in the future, the Company and OSR specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's and OSR's assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements. Additional information concerning certain of these risk factors is contained in the Company's most recent filings with the
Media Contact
Tae Min Lee
OSR Holdings Co., Ltd.
Analyst
taemin.lee@osr-holdings.com
Investor Contact
Kuk Hyoun Hwang
OSR Holdings, Inc.
Chairman & CEO
peter.hwang@osr-holdings.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/osr-holdings-inc-and-osr-holdings-co-ltd-announce-completion-of-business-combination-302377405.html
SOURCE OSR Holdings Inc.
FAQ
When will OSR Holdings (OSRH) start trading on Nasdaq?
What are the new trading symbols for OSR Holdings after the business combination?
What was OSR Holdings' previous company name before the business combination?
When did OSR Holdings complete its business combination?
